No Data
No Data
No Data
No Data
No Data
Weak Financial Prospects Seem To Be Dragging Down Shanghai Shen Lian Biomedical Corporation (SHSE:688098) Stock
With its stock down 37% over the past three months, it is easy to disregard Shanghai Shen Lian Biomedical (SHSE:688098). To decide if this trend could continue, we decided to look at its weak fundam
Simply Wall StApr 16 22:31 ET
Shenlian Biotech (688098.SH): 2023 net profit of 31,518,700 yuan decreased by 48.42% year-on-year
Gelonghui, Feb. 28, 丨 Shenlian Biotech (688098.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 301.4871 million yuan, down 8.25% from the previous year; net profit attributable to owners of the parent company was 31.518,700 yuan, down 48.42% from the previous year.
Gelonghui FinanceFeb 28 06:05 ET
Pinning Down Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) P/S Is Difficult Right Now
When close to half the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3x, you may consider Shanghai Shen Lian Biomedical Corporation (SHSE:688098) as a
Simply Wall StFeb 2 00:43 ET
[BT Financial Report Instantaneous Analysis] Shenlian Biotech's 2023 Quarterly Report: Performance and Market-based Sales Process in the Face of Challenges
Shenlian Biomedical (Shanghai) Co., Ltd. (stock code: 688098) is a high-tech enterprise focusing on R&D, production and sales of veterinary biological products. The company's main business is veterinary preventive biological products and veterinary diagnostic products, and has two major veterinary drug GMP production bases in Shanghai and Lanzhou. The products already marketed by Shenlian Biotech include pig foot-and-mouth disease vaccine, cattle and sheep foot-and-mouth disease vaccine, swine ring vaccine, foot-and-mouth disease and African swine fever diagnostic reagents. Among them, pig foot-and-mouth disease type O and type A bivalent inactivated vaccines are important products of the company. In terms of assets and liabilities, Shenlian Biotech's 2023 three-quarter report shows that the public
businesstimes cnNov 28, 2023 00:04 ET
Shanghai Hongchao, a shareholder of Shenlian Biotech (688098.SH), and his co-actors reduced their holdings of the company by a total of 2.35%
Shenlian Biotech (688098.SH) announced that Shanghai Hongchao Industrial Investment Co., Ltd. (“Shanghai Hongchao”), a shareholder of the company...
Zhitong FinanceNov 24, 2023 03:45 ET
Shenlian Biotech (688098.SH) obtained the “Veterinary Drug GMP Certificate” and the “Veterinary Drug Production License”
Shenlian Biotech (688098.SH) issued an announcement. The company's Lanzhou branch recently passed the veterinary drug GMP inspection and...
Zhitong FinanceNov 20, 2023 03:00 ET
No Data
No Data